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Abstract- Patients with heart failure (HF) are frequently admitted for episodes of decompensation. Cardiac 
troponins are easily accessible biomarkers role of which for risk stratification of re-hospitalization among HF 
patients is less certain. We aimed to evaluate high-sensitive cardiac troponin I (hs-cTnI) levels among re-
hospitalized patients with decompensated heart failure (D-HF). Consecutive subjects admitted with D-HF to 2 
hospitals in Tehran, during the year 2014 were recruited. Excluded ones were patients with a suspected acute 
coronary syndrome or myocarditis/pericarditis, those with cardiopulmonary resuscitation/DC shock delivery, 
or major complications during or after hospitalization. Along with echocardiography parameters, level of hs-
cTnI was checked at the first hour of hospitalization and 3 months after discharge. The patients were then 
categorized according to having or not having re-hospitalization during 3 months post discharge. A total of 97 
patients were finally recruited. Among re-hospitalized patients, Left ventricular (LV) ejection fraction was 
significantly lower (38±14 % vs. 50 ± 12%; P=0.001), and LV end-systolic dimension was significantly higher 
(44±9 mm vs. 38±11 mm; P=0.012) compared to the other group. Moreover, levels of hs-cTnI were 
significantly higher among the re-hospitalized patients, both at initial visit (0.66±0.43 ng/ml vs 0.51±0.14 
ng/ml, respectively; P=0.017) and at 3 months (0.59±0.48 ng/ml vs 0.48±0.23 ng/ml, respectively; P=0.030). 
This prospective study demonstrated that levels of hs-cTnI (both at the base and at follow up) are higher among 
patients who readmitted during 3 months of hospitalization for D-HF. 
© 2019 Tehran University of Medical Sciences. All rights reserved.  
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Heart failure (HF) is a highly common medical 
condition with a prevalence rate of about 2-3% in the 
general population and 10% (or even more) among 
people aged > 70 years (1,2). From a clinical viewpoint, 
patients with compensated or “stable” heart failure (S-
HF) have no notable complaints. However, those with 
acutely decompensated HF (D-HF) are mostly presented 
to emergency departments with significant clinical 
symptoms such as severe dyspnea (3,4). Those episodes 
of decompensation are harbingers of poor prognosis in 
HF, characterized by 1-year and 5-year mortality rate of 
as high as 37.3% and 78.5%, respectively (5), which 
represents the importance of easily accessible measures 
for better risk stratification of the patients. 
Cardiac troponin (cTn) is a complex of 3 proteins 
(cTnT, cTnI, and cTnC) that are essential for muscle 
contraction by regulating the interaction between actin 
and myosin (6). After myocardial necrosis, cTns are 
released into the circulation that makes them as useful 
biomarkers for diagnosing acute coronary syndrome 
(ACS). Furthermore, many studies have been reported the 
elevation of cTnI and cTnT levels both in S-HF (7-10) 
and D-HF (11-15) even in the absence of ACS. The 
prognostic influence of these biomarkers among patients 
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with HF has also been an interesting field of research in 
recent years. 
The cTnI, from a comparative perspective, is more 
often elevated than cTnT in patients with D-HF (16). 
Conversely, cTnT elevations are more frequently seen in 
the setting of renal failure that is highly prevalent among 
D-HF patients (17,18) making cTnT as less specific in 
this setting. Conventional assays of cTn have been used 
for many years, but high-sensitive cTn assays first were 
used by Missov et al., in 1997 (13) that provided a new 
non-invasive window for more exact assessment of 
cardiomyocyte damage. Today, the analytic capabilities 
of these assays offer several advantages over their 
conventional assay counterparts (19).  
Taking those points into account, we designed the 
present study to confirm and further investigate the 
prognostic implication of cTnI level in patients with HF, 
using a high-sensitive cTnI (hs-cTnI) assay and with 
more focus on re-hospitalization as a primary prognostic 
endpoint.  
  
Materials and Methods 
 
Study patients 
Study subjects were enrolled at two hospitals in 
Tehran, Iran: the Rasoul-e-Akram General Hospital and 
the Shahid Rajaei Heart Hospital. All consecutive 
patients presented with D-HF to the emergency 
departments during the year 2014 were initially recruited. 
Those patients with clinical diagnosis of ACS, both at 
initial evaluation and at follow up, were then excluded. 
Other exclusion criteria for the purposes of this study 
were: the suspected diagnosis of myocarditis or 
pericarditis, cardiopulmonary resuscitation or DC shock 
delivery at emergency department, major complications 
(such as pulmonary emboli, cardiogenic shock, sudden 
cardiac arrest, or death) during hospitalization, and being 
expired within 3 months of discharge from hospital. In 
order to prevent duplicate patient entry, if any repeated 
hospitalizations of each subject after the first time of 
inclusion were omitted. 
 
Study protocol 
The demographic information, as well as the result of 
trans-thoracic echocardiographic evaluation and baseline 
laboratory tests,  were recorded for all recruited patients. 
In addition, a separate blood sample at the first hour of 
hospitalization was collected for each patient for 
measuring the level of hs-cTnI. That sample was sent to 
a single reference laboratory at Shahid Rajaei Heart 
Hospital that used the Acute Care™ cTnl assay on the 
Stratus® CS Acute Care™ Diagnostic System, with 
≤10% CV at the 99th percentile of the normal population. 
A next visit 3 months after discharge was planned for 
all enrolled participants who consented. Along with the 
clinical evaluation of the HF, a second sample for the hs-
cTnI was sent to the same laboratory. The patients were 
then categorized according to re-hospitalization during 3 
months after discharge, and measurements were 
compared between the two categories. 
The study protocol was approved by the ethics 
committee of the Iran University of Medical Sciences, 
and the authors were committed to the Helsinki 
Convention Principles at all stages of research. 
 
Statistical analysis 
The collected information was entered into the SPSS 
16.0 statistical software for analysis. Mean, median 
percentages and standard deviation (SD) were calculated. 
The Chi-square test, the Student’s t-test and the Pearson’s 
Correlation test with their non-parametric equivalents 
were used for data analysis as needed. Backward stepwise 
logistic regression was utilized to find the most important 
independent factors for re-hospitalization. Furthermore, 
the receiver operating characteristic (ROC) curve 
analysis was conducted for finding the best cut-off point 
to determine the patients with the most possibility of re-
hospitalization. All tests were two-tailed, and P less than 




Baseline patient characteristics’ 
After applying the exclusion criteria for more than 
200 patients, 97 were recruited for analysis among whom 
47 (48%) were male; and 9 (9%) were expired after 
discharge. Of survived participants, 16 (%) were re-
hospitalized during 3 months after discharge. Table 1 
summarizes all baseline variables compared between the 
2 groups of patients with and without re-hospitalization. 
As seen, most left ventricular (LV) echocardiographic 
indices differ significantly between the 2 groups. For 
example, LV ejection fraction (EF) was significantly 
lower (P=0.001) among the group of re-hospitalized 
patients (38±14 %) compared to the other group 
(50±12%); and LV-end systolic dimension (ESD) was 
significantly higher (P=0.012) in the former group (44±9 
mm) when compared with the latter one (38±11 mm). 
Similar differences were found for LV end-systolic 
volume (LVESV) and LV end-diastolic volume 
(LVEDV) as seen in table 1. No statistically significant 
difference, however, was found in other comparisons 
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such as patients’ age, sex, medical background, and basic laboratory findings (Table 1). 
 











Age (years) 48 ± 16 50 ± 14 44 ± 17 0.060 
Male Sex: No (% of patients) 47(48) 3 (19) 35 (49) 0.097 
Medical Conditions: 
No(% of patients) 
Diabetes 15(16) 4 (25) 11 (15) 0.311 
Hypertension 21(37) 8 (50) 13 (18) 0.106 
Cigarette Smoking 23(24) 9 (56) 14 (19) 0.081 
Laboratory Findings 
(mg/dl) 
Triglyceride  141 ± 65 133 ± 71 148 ± 59 0.130 
Cholesterol  157 ± 38 161 ± 40 156 ± 36 0.831 
High Density Lipoprotein  45 ± 10 46 ± 10 45 ± 10 0.776 
Low Density Lipoprotein  91 ± 34 92 ± 33 91 ± 35 0.636 
Creatinine      
Echocardiographic 
Indices 
LV Ejection Fraction (%) 44 ± 14 38 ± 14 50 ± 12 0.001 
LV End-Systolic Volume (ml) 84 ± 36 96 ± 38 71 ± 31 0.016 
LV End-Systolic Dimension (mm) 41 ± 11 44 ± 9 38 ± 11 0.012 
LV End-Diastolic Volume (ml) 156 ± 45 158 ± 43 151 ± 48 0.045 
LV End-Diastolic Dimension (mm) 6.1 ± 9 62 ± 7 59 ± 11 0.065 
*Plus-minus values are mean +s standard deviation; NYHA: New York Heart Association, LV: Left ventricle 
** Total of subjects include those who were expired after discharge 
 
 
Measurement of hs-cTnI 
Hs-cTnI levels had statistically significant difference 
among patients with and without diabetes (first-
admission value: 0.69±0.37 vs. 0.61±0.46, respectively, 
P=0.015; follow-up value: 0.62±0.47 vs. 0.59±0.31, 
respectively, P=0.026). No such a meaningful difference 
was found for other baseline characteristics. 
As shown in Table 2, levels of hs-cTnI were 
significantly higher among the re-hospitalized group 
compared to the other group, both at initial visit 
(0.66±0.43 ng/ml vs. 0.51±0.14 ng/ml, respectively; 
P=0.017) and at 3 months (0.59±0.48 ng/ml vs. 0.48±0.23 
ng/ml, respectively; P=0.030). 
 
Table 2. High-Sensitive Cardiac Troponin I (cTnI) levels compared between the two groups of patients 
cTnI level (ng/ml) With Re-hospitalization* Without Re-hospitalization* P 
Initial value 0.66±0.43 0.51±0.14 0.017 
Follow-up value (3-months after 
discharge) 
0.59±0.48 0.48±0.23 0.030 





According to the results of this prospective study, we 
found those patients with D-HF who re-hospitalized 
during 3 months post-discharge had worse 
echocardiographic parameters (LVEF, LVESV, LVESD, 
and LVEDD), and higher levels of hs-cTnI. In addition, 
diabetic patients had higher hs-cTnI level both at D-HF 
and S-HF phases. 
HF as a ubiquitous public health problem has a wide 
spectrum of the clinical picture from completely 
asymptomatic patients with S-HF to those presented with 
near-death D-HF. The echocardiographic parameters, as 
well as biochemical markers (such as cTns), are helpful 
to have a better estimation of the HF status. Clearly, 
worse LV echocardiographic indices identify a subgroup 
of D-HF patients with the worse overall cardiac 
condition. Accordingly and predictably, our re-
hospitalized patients demonstrated worse baseline D-HF 
state as shown on their LV echocardiographic parameters. 
Similar overall results have also been reported in other 
studies (20,21,22). 
Prognostic significance of elevated cTn levels among 
D-HF patients has been demonstrated in many studies 
until now, most of which have been used cTnT rather than 
cTnI for risk stratification (9,10,12,23-25). Also for this 
setting, the novel high-sensitivity assays have less been 
studied than the conventional assays. Although Guisado 
Espartero et al., (26) found cTnT as not having a role in 
predicting re-hospitalization of D-HF patients, others 
Sh. Hajsadeghi, et al. 
    Acta Medica Iranica, Vol. 57, No. 2 (2019)    119 
proved cTnT as a useful predictor of re-hospitalization 
(4,27,28). Along with Tsutamoto et al., (29) and Parenti 
et al., (30) who showed higher cTnI levels have 
prognostic importance among HF patients, Yang Xue et 
al., (31) using a high-sensitivity assay for cTnI, similar to 
our study, demonstrated even very small hs-cTnI 
elevations are associated with increased 90-day D-HF 
readmission. The latter study (31) found patients with 90-
day HF-related re-hospitalization had similar on-
admission hs-cTnI level as patients who were event-free 
and thus emphasized the importance of serial 
measurements of hs-cTnI. In our study, however, a 
statistically significant difference for on-admission hs-
cTnI levels were found among those with and without re-
hospitalization. Collectively, the findings of these 
different studies are in favor of the theory of “ongoing 
myocyte injury.” Considering elevated cTn levels as a 
marker of myocyte death or injury (32), higher levels of 
cTn (e.g. hs-cTnI in our study) among re-hospitalized 
patients could be translated as more ongoing myocyte 
damage which is a multifactorial event itself and several 
pathophysiologic mechanisms such as 
mechanical/oxidative stress, excessive adrenergic 
stimulation, etc. might have a role for it. Although several 
hypotheses have been proposed as an explanation, the 
exact mechanisms by which cTn levels are increased 
among HF patients (in the absence of ACS) remain 
uncertain. Those minimal differences in results of various 
surveys are best ascribed to the different population being 
studied and to different assays being used. For example, 
Christopher et al., (28) found the similar risk of major 
cardiac events between patients with positive on-
admission cTn levels and those who converted to high 
cTn during hospitalization; a finding that best unifies our 
results with the results of Xue et al., (31) mentioned 
earlier. 
Elevated levels of hs-cTnI among diabetics with the 
clinically stable cardiovascular state have been 
previously demonstrated by Yiu et al., (33) and higher hs-
cTnI level was shown to be associated with increased risk 
of major cardiac event. We proved in this study, not only 
at S-HF state but also at D-HF phase the levels of hs-cTnI 
am higher in patients with type 2 diabetes. Arterial 
stiffening (34), as well as such factors as higher oxidative 
stress (35,36) and role of advanced glycosylated end-
products (37), have been proposed for subtle myocardial 
injury and so elevated levels of cTns among diabetics. 
As the main limitation, the present 2-center study 
recruited a relatively small population of HF patients. The 
higher sample size is needed to improve the power of 
future surveys. Moreover, we neither compared patients’ 
medications among the 2 groups nor focused on the 
subjects’ adherence to the standard HF treatment; issues 
that might be subjected as potential confounders for the 
results. Our strict exclusion criteria, however, made the 
results to be best limited to the HF population with no 
major confounding situation. Using high-sensitivity assay 
for cTn (rather than conventional assay), and using more 
sensitive cTnI rather than cTnT (33) might be considered 
as other advantages of the present investigation. 
In conclusion, in a prospective evaluation, we 
demonstrated that levels of hs-cTnI (both at the base and 
at follow up) are higher among HF patients who 
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